Evidence map›Paper›PMID 19850955›Full record

Trial reportJournal of the American Society of Nephrology : JASN2009

Left ventricular geometry predicts cardiovascular outcomes associated with anemia correction in CKD.

Kai-Uwe Eckardt, Armin Scherhag, Iain C Macdougall, Dimitrios Tsakiris, Naomi Clyne, Francesco Locatelli, Michael F Zaug, Hans U Burger, Tilman B Drueke

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the American Society of Nephrology : JASN, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. The Role of Two Heart Biomarkers in IgA Nephropathy.International journal of molecular sciences · 2023
    Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Observational
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kai-Uwe EckardtDepartment of Nephrology and Hypertension, University of Erlangen-Nuremberg, Krankenhausstrasse 12, Erlangen, Germany. med4@uk-erlangen.de
Armin Scherhag
Iain C Macdougall
Dimitrios Tsakiris
Naomi Clyne
Francesco Locatelli
Michael F Zaug
Hans U Burger
Tilman B Drueke

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Partial correction of anemia in patients with chronic kidney disease (CKD) reduces left ventricular hypertrophy (LVH), which is a risk factor for cardiovascular (CV) morbidity, but complete correction of anemia does not improve CV outcomes. Whether LV geometry associates with CV events in patients who are treated to different hemoglobin (Hb) targets is unknown. One of the larger trials to study the effects of complete correction of anemia in stages 3 to 4 CKD was the Cardiovascular Risk Reduction by Early Anemia Treatment with Epoetin Beta (CREATE) trial. Here, we analyzed echocardiographic data from CREATE to determine the prevalence, dynamics, and prognostic implications of abnormal LV geometry in patients who were treated to different Hb targets. The prevalence of LVH at baseline was 47%, with eccentric LVH more frequent than concentric. During the study, LVH prevalence and mean left ventricular mass index did not change significantly, but LV geometry fluctuated considerably within 2 yr in both groups. CV event-free survival was significantly worse in the presence of concentric LVH and eccentric LVH compared with the absence of LVH (P = 0.0009 and P < or = 0.0001, respectively). Treatment to the higher Hb target associated with reduced event-free survival in the subgroup with eccentric LVH at baseline (P = 0.034). In conclusion, LVH is common and associates with poor outcomes among patients with stages 3 to 4 CKD, although both progression and regression of abnormal LV geometry occur. Complete anemia correction may aggravate the adverse prognosis of eccentric LVH.

Indexed as

AdultAgedAnemiaCardiovascular DiseasesDisease-Free SurvivalEchocardiographyErythropoietinFemaleHeart VentriclesHemoglobinsHumansHypertrophy, Left VentricularKaplan-Meier EstimateMaleMiddle AgedPrognosisepoetin betaErythropoietinHemoglobinsRecombinant Proteins

Identifiers

PMID19850955
PMCPMC2794228

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.